𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Averting Dementia of the Alzheimer's Type in Women: Can Counselors Help?

✍ Scribed by Kathryn Z. Douthit


Publisher
American Counseling Association
Year
2007
Tongue
English
Weight
178 KB
Volume
6
Category
Article
ISSN
1524-6817

No coin nor oath required. For personal study only.

✦ Synopsis


Alzheimer's disease (AD) is the most common cause of dementia in late life, taking its greatest toll on women over age 80. This article provides an overview of AD, including risk factors and counseling strategies targeting risk. Counseling strategies address stress, cardiovascular health, social integration, depression, and holistic wellness.

The life experiences of women, their educational and vocational opportunities, their access to health care, medications, and disease exposures may affect their risks of Alzheimer's Disease in ways that current research is only beginning to comprehend.

-Lerner, 1999, p. 1831

Among the many challenges encountered in late life, a diagnosis of dementia is particularly devastating. Not only does the diagnosis represent a personal tragedy for those with dementia, it portends a harrowing experience for families and other caregivers. One of the best known forms of dementia, dementia of the Alzheimer's type (DAT), is a disorder that, as its name indicates, is an outcome of the Alzheimer's disease (AD) process. As is the case for all dementias, DAT presents affected individuals with an array of cognitive deficits and emotional struggles. Unlike most other forms of dementia, however, the impact of DAT is greater on women than it is on men (Baum, 2005).

Although DAT remains an incurable, dreaded disorder, contemporary research in the biomedical sciences suggests that there is some hope that the disease can be averted. There are, in fact, a host of strategies, many falling within the purview of counseling practice, which may be able to alter the progression of the AD process. This article explores the role of counseling in averting the devastating effects of DAT, giving particular attention to how counselors can help women in the fight against AD. It begins with an overview of the statistics, symptoms, etiology, pathology, and risk factors related to the disorder. Strategies for controlling the symptoms of DAT are then considered and are followed by


πŸ“œ SIMILAR VOLUMES


Can clock drawing test help to different
✍ Jeremia Heinik; Isaac Solomesh; Boris Raikher; Ruth Lin πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 60 KB πŸ‘ 2 views

## Objectives: The purpose of this preliminary study was to determine if clock drawing performance may help to differentiate between dementia of the alzheimer's type (dat) and vascular dementia (vd) patients. ## Methods: Eighty-eight community-dwelling outpatients were comprehensively evaluated a

Behavioural disturbances in psychiatric
✍ Jen-Ping Hwang; Cheng-Hung Yang; Shih-Jen Tsai; King-Ming Liu πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 109 KB πŸ‘ 2 views

This report studied behavioural disturbances in psychiatric inpatients with dementia of the Alzheimer's type (DAT) in Taiwan. The sample consisted of 75 inpatients with DAT who were consecutively admitted to the geropsychiatric ward. Their behavioural disturbances were obtained from semistructured i

The Mini-Mental State exam may help in t
✍ Thomas A. Ala; Larry F. Hughes; Gregory A. Kyrouac; Mona W. Ghobrial; Rodger J. πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 88 KB πŸ‘ 2 views

## Objective: Since patients with dementia with lewy bodies (dlb) tend to have greater impairment of attention and construction and better memory ability on neuropsychological tests than patients with alzheimer's disease (ad), we determined if the items that measure attention, memory, and construct

Oxiracetam in the treatment of primary d
✍ Stephen R. Dager; J. Pierre Loebel; Keith Claypool; Mary Case; Christopher B. Bu πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 602 KB

## Abstract A 16‐week open‐label trial of high‐dose oxiracetam (up to 3200 mg per day), was not clinically effective overall in treating a small cohort of patients with mild‐moderate dementia of the Alzheimer's type (DAT). However, one of six patients did demonstrate evidence of progressive clinica